Goette, Andreas, Corradi, Domenico, Dobrev, Dobromir, Aguinaga, Luis, Cabrera, Jose-Angel, Chugh, Sumeet, de Groot, Joris, Soulat-Dufour, Laurie, Fenelon, Guilherme, Hatem, Stephane, Jalife, Jose, Lin, Yenn-Jiang, Lip, Gregory, Marcus, Gregory, Murray, Katherine, Pak, Hui-Nam, Schotten, Ulrich, Takahashi, Naohiko, Yamaguchi, Takanori, Zoghbi, William, Nattel, Stanley, Mont, Lluis, Akar, Joseph, Akoum, Nazem, Althoff, Till, Diaz, Juan, Guichard, Jean-Baptiste, Jadidi, Amir, Kalman, Jonathan, Lim, Han, and Teixeira, Ricardo
AIMS: The concept of atrial cardiomyopathy (AtCM) had been percolating through the literature since its first mention in 1972. Since then, publications using the term were sporadic until the decision was made to convene an expert working group with representation from four multinational arrhythmia organizations to prepare a consensus document on atrial cardiomyopathy in 2016 (EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication). Subsequently, publications on AtCM have increased progressively. METHODS AND RESULTS: The present consensus document elaborates the 2016 AtCM document further to implement a simple AtCM staging system (AtCM stages 1-3) by integrating biomarkers, atrial geometry, and electrophysiological changes. However, the proposed AtCM staging needs clinical validation. Importantly, it is clearly stated that the presence of AtCM might serve as a substrate for the development of atrial fibrillation (AF) and AF may accelerates AtCM substantially, but AtCM per se needs to be viewed as a separate entity. CONCLUSION: Thus, the present document serves as a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS) to contribute to the evolution of the AtCM concept.